Figure 1.

Expression profiles of FcγRIIB in WT and mutant mice with germline or conditional knockout of Fcgr2b. (A) Histogram profiles showing the expression of FcγRIIB in the indicated cell types of the indicated mice. FcγRIIB levels were analyzed in B cells (CD19⁺), monocytes (CD11b⁺NK1.1^-Gr1^low/−SSC^low) and neutrophils (CD11b⁺NK1.1⁻Gr1^highSSC^int) in the peripheral blood, and dendritic cells (DC, CD11c^high) in the spleen in WT C57BL/6 mice, and mice with germline or conditional knockout of Fcgr2b. (B) The gating strategy for non-germinal center B cells, IgG1⁺ and IgG1⁻ GC B cells, and histogram profiles showing Cg1Cre-mediated deletion of Fcgr2b in these cells. Mice with the indicated genotypes were treated with NP-CGG in alum and analyzed 12 days later for the expression of FcγRIIB in splenic non-GC B cells (B220⁺Fas⁻), IgG1⁺ and IgG1⁻ GC B cells (B220⁺Fas⁺IgG1⁺ and B220⁺Fas⁺IgG1⁻, respectively). (C) Histogram profiles showing FcγRIIB levels in thioglycollate-elicited macrophages (CD11b⁺F4/80⁺) isolated from mice of the indicated genotypes. Representative of two independent experiments with 3 mice per group.